If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-20. Numbers and descriptions here follow the published literature rather than marketing material.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
=== Mass-18 notation === Under some circumstances, the abundances of 13CH3D and 12CH2D2 isotopologues are only measured as a sum, which leads to the notation for isotopologues of mass-18 (i.e. 13CH3D and 12CH2D2):
The initiative's sponsor associations include United Fresh Produce Association (United Fresh), Canadian Produce Marketing Association (CPMA) and Produce Marketing Association (PMA). Both internal and external traceability programs are needed in order to effectively track and trace product up and down the supply chain, achieving whole-chain traceability. At present, most companies have internal traceability programs but not external traceability. The PTI outlines a six-step course of action to achieve chain-wide adoption of electronic traceability of every case produce by the year 2012. Meanwhile, companies are putting into operation technologies that will support the PTI.
After the jerky is dried to the proper moisture content to prevent spoilage, it is cooled and then packaged in (often resealable) plastic bags, either nitrogen gas flushed or vacuumed packed. The sealed packages usually contain small pouches of oxygen absorber to avoid fat oxidation. These small packets are filled with iron particles, which react with oxygen, removing the oxygen from the sealed jerky package and from an opened and resealed unfinished packet. Because of the necessary low fat and moisture content, jerky is high in protein. For example, a 30 g (about 1 oz) portion of lean meat contains about 7 g of protein. By removing 15 g of water from the meat, the protein ratio is doubled to nearly 15 g of protein per 30 g portion. In some low moisture varieties, a 30 g serving will contain 21 g of protein, and only one g of fat. The price per unit weight of this type of jerky is higher than less-dried forms, as it takes 90 g of 99% lean meat to generate 30 g of jerky. Unpackaged fresh jerky made from sliced, whole-muscle meat has been available in specialty stores in such places as Hong Kong at least since the 1970s. The products are purchased in kilograms, and customers choose from 10 to 20 types of meat used to make the product. Some are sold in strands instead of slices. Compared to the sealed packaged versions, unpackaged jerky has a relatively short shelf life. This type of jerky has also become very popular in convenience stores in the United States, where it is usually sold in clear plastic containers under the name "slab" jerky.
This research provided a new drug that could serve as a new treatment for amebiasis caused by the Entamoeba histolytica. In 2017, auranofin completed phase I clinical trials against Entamoeba histolytica and Giardia The Barrios Lab in the Department of Pharmacy at the University of Utah largely focuses on developing chemical probes to study biological substrates, substrate selectivity, cellular regulation, and druggability for use in therapeutics. Human protein tyrosine phosphatases (PTPs) hold substantial relevance in human autoimmunity and T-cell receptor signaling, as well as cell signaling in diseases. Novel chemical probes to better understand the activity and regulation of this family of enzymes aids in developing human therapeutics. These developments in the Barrios Lab include fluorogenic probes to investigate PTP activity, along with profiling substrate selectivity for the use of developing potent, selective inhibitors. Additionally, the Barrios Lab also focuses on chemical tools used to study the therapeutic roles of metal ions as biological targets of gold-based compounds.
Sources: en.wikipedia.org
Because this process removes/inactivates the lipid coating of a virus, viruses without any sort of lipid envelope will be unaffected. There is also no inactivation effect by the buffers used in this process.
The lack of organization structure has led to project cancellations, as it can be difficult to convince other employees to work on them. In 2020, Valve acknowledged that this made it difficult to gather momentum and had slowed its output during the 2010s. Its VR projects and Half-Life: Alyx became a turning point, setting short-term studio-wide goals to focus the company. According to Walker, "We sort of had to collectively admit we were wrong on the premise that you will be happiest if you work on something you personally want to work on the most." In January 2023, People Make Games released a report on Valve's corporate structure and culture, based on interviews with several current and former employees. They found that Valve's flat structure and stack-ranking compensation system created a poor release record and a lack of employee diversity. In 2024, Forbes estimated that Newell owned 50.1% of Valve, with the rest owned by employees. As part of Wolfire Games' lawsuit over Steam policies, case documents revealed details related to Valve's employee structure. Valve had 60 employees in 2003 and had approximately 350 employees between 2012 and 2021. Employees are categorized into administration, game development, Steam development and (from 2011) hardware development.
Intracellular Ang II is generated within cardiac cells either through internalization of circulating Ang II or by intracellular synthesis via non-secreted renin and angiotensinogen. Unlike its extracellular counterpart, intracrine Ang II does not rely on traditional cell surface receptors; instead, it binds to nuclear AT1 receptors, modulating gene transcription and intracellular signaling pathways. Studies have demonstrated that intracrine Ang II localizes to the nucleus and mitochondria of cardiac myocytes, where it influences cellular metabolism, oxidative stress, and calcium homeostasis. Additionally, intracellular Ang II has been shown to enhance the transcription of genes involved in hypertrophy and fibrosis, contributing to pathological cardiac remodeling.
== Reception == John Dickson Carr, a writer of locked-room mysteries, has his detective Dr. Gideon Fell declare this the "best detective tale ever written", in his novel The Hollow Man (1935). Agatha Christie praised The Mystery of the Yellow Room through the mouthpiece of her detective Hercule Poirot in her 1963 novel The Clocks:
=== ConSurf === Ben-Tal has led the development of ConSurf, a computational method and web server that uses evolutionary information to identify potentially functionally important regions in proteins. The methodology maps evolutionary conservation scores onto three-dimensional molecular structures, allowing conserved regions of a protein to be visualized on its surface. The original ConSurf work was published in Bioinformatics in 2003 by a team that included Ben-Tal, Fabian Glaser, Tal Pupko, Inbal Paz, Rachel E. Bell, Dalit Bechor-Shental, and Eric Martz. The ConSurf project has subsequently been expanded through successive versions and databases. A 2016 paper described an updated methodology for estimating and visualizing evolutionary conservation in macromolecules, while later work produced ConSurf-DB, a repository containing precomputed evolutionary conservation profiles for proteins with known structures. Ben-Tal has continued to contribute to the development of ConSurf. A 2023 paper described a revised version of the system for using evolutionary information to analyze macromolecules.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.